Glucarpidase following high-dose methotrexate: update on development

Bibliography

• Demirdjian S, Laghouati S, Vassal G. Glucarpidase: a method of rescue from high dose methotrexate. Eur J Oncol Pharm 2008;2(1):20-1
   Google Scholar
• Jolivet J, Cowan KH, Curt GA, The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309(18):1094-104
   PubMed Web of Science ®Google Scholar
• Frei E III, Blum RH, Pitman SW, High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 1980;68(3):370-6
   PubMed Web of Science ®Google Scholar
• Stoller RG, Hande KR, Jacobs SA, Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977;297(12):630-4
   PubMed Web of Science ®Google Scholar
• Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977;4(2):87-101
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Murphy RF, Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997;15(5):2125-34
   PubMed Web of Science ®Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11(6):694-703
   PubMed Web of Science ®Google Scholar
• Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987;5(12):2017-31
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Stoller RG, Chabner BA, Johns DG. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 1976;57(2):534-8
   PubMed Web of Science ®Google Scholar
• Lankelma J, van der Klein E, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett 1980;9(2):133-42
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Kempf-Bielack B, High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100(10):2222-32
   PubMed Web of Science ®Google Scholar
• Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 2009;63(4):599-604
   PubMed Web of Science ®Google Scholar
• Wall SM, Johansen MJ, Molony DA, Effective clearance of methotrexate using high-flex hemodialysis membranes. Am J Kidney Dis 1996;28(6):846-54
   PubMed Web of Science ®Google Scholar
• Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 1999;17(5):1589-94
   PubMed Web of Science ®Google Scholar
• Skarby TV, Anderson H, Heldrup J, High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukaemia. Leukemia 2006;20(11):1955-62
   PubMed Web of Science ®Google Scholar
• Cohen IJ. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. Pediatr Hematol Oncol 2003;20(8):579-81
   PubMed Web of Science ®Google Scholar
• Goldman P, Levy CC. The enzymatic hydrolysis of folate analogues. Biochem Pharmacol 1968;17(11):2265-70
   PubMed Web of Science ®Google Scholar
• Levy CC, Goldman P. The enzymatic hydrolysis of methotrexate and folic acid. J Biol Chem 1967;242(12):2933-8
   PubMed Web of Science ®Google Scholar
• Widemann BC, Sung E, Anderson L, Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N10-methylpteroic acid. J Pharmacol Exp Ther 2000;294(3):894-901
   PubMed Web of Science ®Google Scholar
• Chabner BA, Johns DG, Bertino JR. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature 1972;239(5372):395-7
   PubMed Web of Science ®Google Scholar
• Abelson HT, Ensminger W, Rosowsky A, Uren J. Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics. Cancer Treat Rep 1978;62(10):1549-52
   PubMedGoogle Scholar
• Abelson HT, Kufe DW, Skarin AT, Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep 1981;65:(Suppl 1):137-40
   PubMedGoogle Scholar
• Adamson PC, Balis FM, McCully CL, Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. J Clin Oncol 1992;10(8):1359-64
   PubMed Web of Science ®Google Scholar
• Minton NP, Atkinson T, Sherwood RF. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 1983;156(3):1222-7
   PubMed Web of Science ®Google Scholar
• Sherwood RF, Melton RG, Alwan SM, Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem 1985;148(3):447-53
   PubMedGoogle Scholar
• Hempel G, Lingg R, Boos J. Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications. Cancer Chemother Pharmacol 2005;55(4):347-53
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Tong WP, Lin S, Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol 1996;14(7):2145-9
   PubMed Web of Science ®Google Scholar
• Adamson PC, Balis FM, McCully CL, Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol 1991;9(4):670-4
   PubMed Web of Science ®Google Scholar
• Headley D, Ogilvie L, Springer CJ. Carboxypeptidase G2-based gene-directed enzyme–prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer 2007;7:870-79
   PubMed Web of Science ®Google Scholar
• Marais R, Spooner RA, Light Y, Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res 1996;56:4735-42
   PubMed Web of Science ®Google Scholar
• Phillips M, Smith W, Balan G, Ward S. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. J Clin Pharmacol 2008;48(3):279-84
   PubMed Web of Science ®Google Scholar
• Grill J, Amigo-Ferreiro ME, Schoepfer C, Carboxypeptidase-G2 rescue of methotrexate intoxication. Bull Cancer 1998;85(12):1066. Erratum in: Bull Cancer 1999 86(2):232
   Google Scholar
• Hum M, Kamen BA. Successful carboxypeptidase G2 rescue in delayed MTX-elimination due to renal failure. Pediatr Hematol Oncol 1995;12(6):521-4
   PubMed Web of Science ®Google Scholar
• Krause AS, Weihrauch MR, Bode U, Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma 2002;43(11):2139-43
   PubMed Web of Science ®Google Scholar
• Mantadakis E, Rogers ZR, Smith AK, Delayed methotrexate clearance in a patient with sickle cell anemia and osteosarcoma. J Pediatr Hematol Oncol 1999;21(2):165-9
   PubMed Web of Science ®Google Scholar
• Mohty M, Peyriere H, Guinet C, Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure. Leuk Lymphoma 2000;37(3-4):441-3
   PubMed Web of Science ®Google Scholar
• Nowicki TS, Bjornard K, Kudlowitz D, Early recognition of renal toxicity of high-dose methotrexate therapy: a case report. J Pediatr Hematol Oncol 2008;30(12):950-2
   PubMed Web of Science ®Google Scholar
• Peyriere H, Cociglio M, Margueritte G, Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother 2004;38(3):422-7
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Rimpler M, Herrmann R, Josting A. Successful carboxypeptidase G2 rescue of a high-risk elderly Hodgkin lymphoma patient with methotrexate intoxication and renal failure. Leuk Lymphoma 2007;48(8):1641-3
   PubMed Web of Science ®Google Scholar
• Snyder RL. Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use. Am J Health Syst Pharm 2007;64(11):1163-9
   PubMed Web of Science ®Google Scholar
• Widemann BC, Hetherington ML, Murphy RF, Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 1995;76(3):521-6
   PubMed Web of Science ®Google Scholar
• Zoubek A, Zaunschirm HA, Lion T, Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol 1995;12(5):471-7
   PubMed Web of Science ®Google Scholar
• Buchen S, Ngampolo D, Melton RG, Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005;92(3):480-7
   PubMed Web of Science ®Google Scholar
• Schwartz S, Borner K, Müller K, Glucarpidase (carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007;12(11):1299-308
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Shalabi A, Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 2004;96(20):1557-9
   PubMed Web of Science ®Google Scholar
• Withdrawal assessment report for Voraxaze. International nonproprietary name: glucarpidase. EMEA/H/C/681, London, UK: EMEA, 2008. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/voraxaze/H-681-WAR-en.pdf [Last accessed 10 November 2009]
   Google Scholar
• Voraxaze. BTG, London UK. Available from: http://www.btgplc.com/BTGPipeline/273/Voraxaze.html [Last accessed 10 November 2009]
   Google Scholar